What's in Pierre Fabre Medicament's pipeline?

Pierre Fabre Medicament has 37 drugs in our index: 5 marketed, 0 filed, 9 in Phase 3, 11 in Phase 2, 12 in Phase 1.

Which companies overlap with Pierre Fabre Medicament's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, Pfizer, Bausch & Lomb Incorporated.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/pierre-fabre-medicament.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Pierre Fabre Medicament — Portfolio Competitive Intelligence Brief

Pierre Fabre Medicament pipeline: 5 marketed, 0 filed, 9 Phase 3, 11 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 9 Phase 3 11 Phase 2 12 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Placebo matching Tamsulosine LP	Placebo matching Tamsulosine LP	marketed	Alpha-1A adrenergic receptor antagonist (active comparator: tamsulosin)	Alpha-1A adrenergic receptor	Urology
Tamsulosine Arrow LP	Tamsulosine Arrow LP	marketed	Alpha-1A adrenergic receptor antagonist	Alpha-1A adrenergic receptor	Urology
Tamsulosine LP	Tamsulosine LP	marketed
Placebo matching Tamsulosine Arrow LP	Placebo matching Tamsulosine Arrow LP	marketed	Placebo (matching formulation)		Urology
DC071	DC071	marketed			Other
J022X ST	J022X ST	phase 3			Oncology
Locapred@	Locapred@	phase 3	Topical corticosteroid	Glucocorticoid receptor	Dermatology
V0034CR01B	V0034CR01B	phase 3	BTK inhibitor	BTK	Oncology
vinflunine and best supportive care	vinflunine and best supportive care	phase 3	Anthracycline antibiotic	Topoisomerase II	Oncology
Locatop@	Locatop@	phase 3	Topical corticosteroid	Glucocorticoid receptor	Dermatology
F2695	F2695	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)	Oncology
desonide 0.1% cream	desonide 0.1% cream	phase 3	Corticosteroid	Glucocorticoid receptor	Dermatology

Therapeutic area mix

Oncology · 7
Dermatology · 3
Other · 3
Urology · 3
Diabetes · 1
Respiratory · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 6 shared drug classes
AstraZeneca · 5 shared drug classes
Eli Lilly and Company · 5 shared drug classes
Pfizer · 4 shared drug classes
Bausch & Lomb Incorporated · 2 shared drug classes
Aswan University Hospital · 2 shared drug classes
Allergan · 2 shared drug classes
AbbVie · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Pierre Fabre Medicament:

Cite this brief

Drug Landscape (2026). Pierre Fabre Medicament — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pierre-fabre-medicament. Accessed 2026-05-16.